A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

This study has been withdrawn prior to enrollment.
(GSK2248761 development program is on clinical hold.)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT01273103
First received: January 6, 2011
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

This study is a Phase I, open-label, single dose, mass balance study in a cohort of 6 healthy adult male subjects. The study will consist of: Screening evaluations, a treatment phase, and follow-up evaluations. In the treatment phase, after an overnight fast of at least 10 hours, each subject will receive a single oral suspension dose of GSK2248761 200mg containing [14C] - GSK2248761. Following dosing, serial whole blood, plasma, urine, and fecal samples will be collected. Subjects will be required to remain in the unit until the radiocarbon excreted falls to less than or equal to 1% of the administered dose for two consecutive 24-hour collections in both urine and feces, whichever occurs first. Safety will be assessed by vital signs, 12-lead electrocardiogram (ECG), clinical laboratory tests, AE monitoring, and physical examinations as indicated.


Condition Intervention Phase
Infection, Human Immunodeficiency Virus
Drug: 200mg [14C]- GSK2248761
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: An Open Label, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 200 mg, Administered as an Oral Suspension to Healthy Adult Subjects

Resource links provided by NLM:


Further study details as provided by ViiV Healthcare:

Primary Outcome Measures:
  • Percent recovery of total radiocarbon in urine and feces [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve from time zero to last time of quantifiable concentration within a subject (AUC (0-t)) of total drug-related material (radiocarbon) in blood and plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve from time zero extrapolated to infinite time (AUC (0-infinity)) of total drug-related material (radiocarbon) in blood and plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex) of total drug-related material (radiocarbon) in blood and plasma. [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Minimum observed concentration (Cmax) of total drug-related material (radiocarbon) in blood and plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Time occurence of Cmax (tmax) of total drug-related material (radiocarbon) in blood and plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Terminal phase rate constant (lambda z) of total drug-related material (radiocarbon) in blood and plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Lag time before observation of drug concentrations in sampled matrix (tlag) of total drug-related material (radiocarbon) in blood and plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Terminal phase half life (t1/2) of total drug-related material (radiocarbon) in blood and plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • AUC (0-t) of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • AUC (0-infinity) of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • %AUCex of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Cmax of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • tmax of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Lambda z of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • tlag of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Apparent clearance following oral dosing (CL/F) of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Apparent volume of distribution after oral administration (Vz/F) of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • t1/2 of GSK2248761 in plasma [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability parameters including number of adverse events (AEs) [ Time Frame: up to 25 days ] [ Designated as safety issue: No ]
  • Safety and tolerability parameters including change from baseline for vital signs (blood pressure and heart rate) [ Time Frame: up to 25 days ] [ Designated as safety issue: No ]
  • Safety and tolerability parameters including change from baseline for electrocardiogram assessments (ECGs) [ Time Frame: up to 25 days ] [ Designated as safety issue: No ]
  • Safety and tolerability parameters including change from baseline for clinical laboratory assessments [ Time Frame: up to 25 days ] [ Designated as safety issue: No ]
  • Blood:plasma ratio of total drug-related material (radioactivity) [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]
  • Percent of total radiocarbon associated with red blood cells [ Time Frame: up to 10 days ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: January 2011
Estimated Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
[14C]- GSK2248761 200 mg
Drug: 200mg [14C]- GSK2248761
single oral suspension dose of [14C]- GSK2248761 200 mg

Detailed Description:

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship

  Eligibility

Ages Eligible for Study:   30 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • Male subjects between 30 and 55 years of age.
  • Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 84 days after the dose of study medication. Male subjects also must refrain from the donation of sperm during this time as well.
  • Body weight greater than or equal to 50 kg and body mass index (BMI) within the range 18.5-31.0 kg/m2 (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Available to complete the study (minimum of 7 and a maximum of 11 night's confinement in the clinical research unit).
  • A history of regular bowel movements (averaging one or more bowel movements per day).
  • AST, ALT, alkaline phosphatase and bilirubin greater than or equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). A single repeat is allowed for eligibility determination.

Exclusion Criteria:

  • The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Use of prescription or non-prescription drugs, including antacids, vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • If heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  • History of regular alcohol consumption within 6 months of the study
  • Has a history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
  • Subjects who have received a total body radiation dose of greater than 5.0 mSv (upper limit of WHO category II) or exposure to significant radiation (e.g. serial x-ray or CT scans, barium meal etc) in the 12 months prior to this study. Any previous radiolabeled study drug must have been received more than 6 months prior to check-in. Also the total exposure from this current study and any previous studies must be within the recommended levels considered safe of 5 Rems whole body annual exposure, as per United States (US) Code of Federal Regulations (CFR) 21 CFR 361.1.
  • Any condition that could interfere with the accurate assessment and recovery of radiocarbon [14C].
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy should be excluded.
  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  • A positive test for HIV antibody.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 45-100 bpm. A single repeat is allowed to determine eligibility.
  • An abnormal ECG as specified in the protocol (a single repeat is allowed for eligibility determination).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01273103

Locations
United States, Wisconsin
GSK Investigational Site
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
ViiV Healthcare
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials ViiV Healthcare
  More Information

No publications provided

Responsible Party: ViiV Healthcare
ClinicalTrials.gov Identifier: NCT01273103     History of Changes
Other Study ID Numbers: 113393
Study First Received: January 6, 2011
Last Updated: May 15, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on September 16, 2014